Iván Díaz-Padilla

3.4k total citations
53 papers, 1.4k citations indexed

About

Iván Díaz-Padilla is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Iván Díaz-Padilla has authored 53 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 17 papers in Pulmonary and Respiratory Medicine and 15 papers in Molecular Biology. Recurrent topics in Iván Díaz-Padilla's work include Ovarian cancer diagnosis and treatment (14 papers), Advanced Breast Cancer Therapies (11 papers) and Cancer Treatment and Pharmacology (9 papers). Iván Díaz-Padilla is often cited by papers focused on Ovarian cancer diagnosis and treatment (14 papers), Advanced Breast Cancer Therapies (11 papers) and Cancer Treatment and Pharmacology (9 papers). Iván Díaz-Padilla collaborates with scholars based in United States, Canada and Spain. Iván Díaz-Padilla's co-authors include Eitan Amir, Lillian L. Siu, Philippe L. Bédard, Mustafa Al-Mubarak, Arnoud J. Templeton, Boštjan Šeruga, Alberto Ocaña, Ian F. Tannock, Francisco Vera-Badillo and Ignacio Durán and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

Iván Díaz-Padilla

52 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Iván Díaz-Padilla United States	21	728	634	392	273	260	53	1.4k
Irina Linkov United States	15	598 0.8×	531 0.8×	275 0.7×	351 1.3×	189 0.7×	27	1.5k
Andrea P. Myers United States	17	299 0.4×	788 1.2×	294 0.8×	202 0.7×	212 0.8×	36	1.3k
Véronique Ouellet Canada	22	493 0.7×	770 1.2×	314 0.8×	205 0.8×	218 0.8×	47	1.4k
Sharad Ghamande United States	22	770 1.1×	579 0.9×	216 0.6×	230 0.8×	476 1.8×	114	1.7k
Faina Bogomolniy United States	15	412 0.6×	976 1.5×	475 1.2×	194 0.7×	596 2.3×	20	1.7k
David Y.H. Choong Australia	18	593 0.8×	1.3k 2.1×	521 1.3×	264 1.0×	224 0.9×	25	1.9k
S M Edgerton United States	13	1.1k 1.5×	748 1.2×	661 1.7×	199 0.7×	163 0.6×	14	1.7k
Tomás Bonome United States	15	457 0.6×	1.2k 1.9×	643 1.6×	211 0.8×	731 2.8×	23	2.0k
Alexander C. Klimowicz Canada	23	653 0.9×	821 1.3×	280 0.7×	188 0.7×	72 0.3×	56	1.5k
Rosalind Glasspool United Kingdom	25	722 1.0×	842 1.3×	193 0.5×	171 0.6×	753 2.9×	86	1.9k

Countries citing papers authored by Iván Díaz-Padilla

Since Specialization

Citations

This map shows the geographic impact of Iván Díaz-Padilla's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Iván Díaz-Padilla with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Iván Díaz-Padilla more than expected).

Fields of papers citing papers by Iván Díaz-Padilla

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Iván Díaz-Padilla. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Iván Díaz-Padilla. The network helps show where Iván Díaz-Padilla may publish in the future.

Co-authorship network of co-authors of Iván Díaz-Padilla

This figure shows the co-authorship network connecting the top 25 collaborators of Iván Díaz-Padilla. A scholar is included among the top collaborators of Iván Díaz-Padilla based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Iván Díaz-Padilla. Iván Díaz-Padilla is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Maio, Michele, Víctor Moreno, Juan Martín-Liberal, et al.. (2025). First-in-human phase 1 study of the ICOS agonist feladilimab on patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer. 13(8). e011475–e011475. 1 indexed citations

Hecht, J. Randolph, Jean‐Marie Michot, David J. Bajor, et al.. (2025). CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid tumours. PubMed. 3(1). 10–10. 1 indexed citations

Telli, Melinda L., Sara M. Tolaney, Geoffrey I. Shapiro, et al.. (2022). Phase 1b study of berzosertib and cisplatin in patients with advanced triple-negative breast cancer. npj Breast Cancer. 8(1). 45–45. 31 indexed citations

Shapiro, Geoffrey I., Robert Wesolowski, Craig Devoe, et al.. (2021). Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours. British Journal of Cancer. 125(4). 520–527. 56 indexed citations

Im, Seock‐Ah, Joohyuk Sohn, Debu Tripathy, et al.. (2018). Ribociclib (RIB) + non-steroidal aromatase inhibitor (NSAI) + goserelin in premenopausal Asian women with hormone-receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): Results from the randomized phase III MONALEESA-7 study. Annals of Oncology. 29. ix13–ix13. 3 indexed citations

Minig, Lucas, et al.. (2016). ecancermedicalscience. ecancermedicalscience. 7. 379–379. 14 indexed citations

Kempf, Emmanuelle, et al.. (2016). Clinical and pathologic features of patients with non-epithelial ovarian cancer: retrospective analysis of a single institution 15-year experience. Clinical & Translational Oncology. 19(2). 173–179. 8 indexed citations

Mayer, Ingrid A., Christian F. Singer, Peter A. Fasching, et al.. (2015). A Phase II study of the safety and efficacy of alpelisib or buparlisib plus letrozole in neoadjuvant treatment of postmenopausal women with HR+/HER2–, PIK3CA mutant or wild-type breast cancer.. Journal of Clinical Oncology. 1 indexed citations

Díaz-Padilla, Iván, Michelle Wilson, Blaise Clarke, et al.. (2015). A phase II study of single-agent RO4929097, a gamma-secretase inhibitor of Notch signaling, in patients with recurrent platinum-resistant epithelial ovarian cancer: A study of the Princess Margaret, Chicago and California phase II consortia. Gynecologic Oncology. 137(2). 216–222. 62 indexed citations

10.

Chiu, Joanne, Sébastien J. Hotte, Christian Kollmannsberger, et al.. (2015). A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI♯9041). Investigational New Drugs. 34(1). 104–111. 15 indexed citations

11.

Loong, Herbert H., Eric Winquist, John Waldron, et al.. (2014). Phase 1 study of nab-paclitaxel, cisplatin and 5-fluorouracil as induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced squamous cell carcinoma of the oropharynx. European Journal of Cancer. 50(13). 2263–2270. 10 indexed citations

12.

Vera-Badillo, Francisco, Arnoud J. Templeton, Iván Díaz-Padilla, et al.. (2013). Androgen Receptor Expression and Outcomes in Early Breast Cancer: A Systematic Review and Meta-Analysis. JNCI Journal of the National Cancer Institute. 106(1). djt319–djt319. 279 indexed citations

13.

Bois, Andreas du, Anne Floquet, Jae‐Weon Kim, et al.. (2013). Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced epithelial ovarian, Fallopian tube, or primary peritoneal cancer (AOC): Results of an international intergroup trial (AGO-OVAR16).. Journal of Clinical Oncology. 31(15_suppl). LBA5503–LBA5503. 49 indexed citations

14.

Díaz-Padilla, Iván, Nuria Romero-Laorden, Eitan Amir, et al.. (2013). Mismatch repair status and clinical outcome in endometrial cancer: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology. 88(1). 154–167. 96 indexed citations

15.

Díaz-Padilla, Iván, Ignacio Durán, Blaise Clarke, & Amit M. Oza. (2012). Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer. Cancer Treatment Reviews. 38(6). 767–775. 36 indexed citations

16.

Díaz-Padilla, Iván, Anaís Malpica, Lucas Minig, et al.. (2012). Ovarian low-grade serous carcinoma: A comprehensive update. Gynecologic Oncology. 126(2). 279–285. 58 indexed citations

17.

Minig, Lucas, et al.. (2012). Therapeutic management of epithelial ovarian cancer during pregnancy. Clinical & Translational Oncology. 15(4). 259–264. 17 indexed citations

18.

Díaz-Padilla, Iván, Albiruni Ryan Abdul Razak, Lucas Minig, Marcus Q. Bernardini, & Josep M. del Campo. (2012). Prognostic and predictive value of CA-125 in the primary treatment of epithelial ovarian cancer: potentials and pitfalls. Clinical & Translational Oncology. 14(1). 15–20. 23 indexed citations

19.

Díaz-Padilla, Iván, Eitan Amir, Sharon Marsh, Geoffrey Liu, & Helen Mackay. (2011). Genetic polymorphisms as predictive and prognostic biomarkers in gynecological cancers: A systematic review. Gynecologic Oncology. 124(2). 354–365. 24 indexed citations

20.

Díaz-Padilla, Iván, Lillian L. Siu, & Ignacio Durán. (2009). Cyclin-dependent kinase inhibitors as potential targeted anticancer agents. Investigational New Drugs. 27(6). 586–594. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact